Clindamycin
Brands Darvocet-N Demerol Dilaudid Dolophine Duragesic MS Contin MSIR tablets, capsules OMS Concentrate Oxycontin OXYIR Percodan RMS Suppositories Toradol Oral QL ; Trilisate Tylox Vioxx PAR ; PAIN MEDICATIONS - RELIEF Lower Cost Generics bulalbital ASA CAF acetaminophen caffeine butalb propranolol Brands Cafergot, Wigraine D.H.E. 45 Fiorinal w codeine Imitrex inj QL ; Imitrex Tabs QL ; Maxalt QL ; Sansert SKIN MEDICATIONS - ORAL Lower Cost Generics cyproheptadine hydroxyzine HCL diphenhydramine 50mg hydroxyzine pamoate Brands Accutane dermatologist consultation suggested ; Oxsoralen oral only ; Trisoralen SKIN MEDICATIONS - TOPICAL Lower Cost Generics clindamycin soln erythromycin soln hydrocortisone cream, oint. 2.5% hydrocortisone lotion 1% hydrocortisone lotion 2.5% lindane selenium sulfide Brands Aclovate Actinex Anusol-HC cream.
POLICY: Regions Hospital prohibits the use, possession, transfer and sale of alcohol and or illegal drugs while working, while on all premises owned or operated by the Hospital, and while operating any Hospital vehicle, machinery or equipment. It also prohibits reporting for work, and working anywhere on behalf of Regions Hospital under the influence of alcohol and or illegal drugs. Violation of this policy may result in discipline, up to and including discharge. "Illegal drugs" means controlled substances, and includes prescription medication which contain a controlled substance and which are used for a purpose or by a person for which they were not prescribed or intended. This policy does not prohibit: a ; the moderate consumption of alcoholic beverages at Hospitalsponsored events, if any, where the Hospital has authorized alcoholic beverages to be served, and b ; the possession of sealed bottles or cans of alcoholic beverages in employee vehicles on Hospital premises so long as this possession would be in compliance with the state law if the vehicle were on a public street, for example, clindamycin phosphate gel. ANESTHETICS -Cont'd Therevac. Vagisil. Xylocaine. ANILERIDINE. Description and cases, p. 33. ANSOLYSEN. See PENTOLINIUM TARTBATE. ANT-USE. See DISULFIBAM. ANTIANXIETY AGENTS. See TBANQUILIZEBS AND ANTIANXIETY AGENTS. ANTIBIOTICS AND ANTIBACTERIALS. Achromycin. Amcill. Amikacin sulfate. An&in. Amiloride. Ampicillin. Aralen. AVC Suppositories. Avlosulfon. Axuliidine. Bactrim. Blephamide. Cefoxitin sodium. Cephalexin monohydrate. Cephalothin sodium. Chloramphenicol. Chloromycetin. Chloroquine. Cleocin hydrochloride. Clidamycin hydrochloride. Cortisporin. Cotrim. Cycloserine. Dapsone. Declomycin. Demeclocycline hydrochloride. Erythromycin estolate. Flagyl. Furadantin. Garamycin. Gentamicin sulfate. G-my&in. Ilosone. NB. Consult BNF for children's doses or check with the clinical pharmacist a ; Amoxicillin 1g iv im induction then amoxicillin 500mg orally 6 hours later. b ; Amoxicillin 3g orally 4 hours before induction then amoxicillin 3g orally as soon as possible after the procedure. c ; Amoxicillin 1g iv im gentamicin 120mg iv im at induction then amoxicillin 500mg orally 6 hours later. d ; Vancomycin 1g ivi over at least 100 minutes then gentamicin 120mg iv at induction or 15 minutes before the procedure. e ; Teicoplanin 400mg iv + gentamicin 120mg iv at induction or 15 minutes before the procedure. f ; Clundamycin 300mg iv over at least 10 minutes ; at induction or 15 minutes before the procedure then oral iv clindamycin 150mg 6 hours later. Basiliximab in both pediatric and adult renal transplant patients [111-113]. In all cases, the reaction was on second exposure, and it was proven to be IgE mediated in 2 of the cases [111, 112]. Interestingly, Leonard et al [111] reported successful administration of daclizumab to a patient following hypersensitivity reaction to basiliximab. The authors hypothesized that lack of reaction to daclizumab may have been related to the smaller quantity of murine protein in the humanized antibody or that altered configuration of the murine protein made it unrecognizable [111]. Thus, this medication and others in its class should be used with caution and only when appropriate supportive care measures are readily available. It may be possible to administer the humanized form of the antibody subsequent to hypersensitivity reaction to the chimeric antibody. The cytokine release syndrome associated with polyclonal antibodies such as ATG ; is thought to be mediated by T-cell release of cytokines such as tumor necrosis factor TNF ; , IL-2, and interferon-. Patients typically present with fever, chills, and gastrointestinal upset. Chest pain, dyspnea, and wheezing as well as pulmonary edema, multiorgan failure, and death may also occur [120]. Complement activation and neutrophil sequestration in the lungs may play a role in pulmonary symptoms [121]. Cytokine release syndrome has been most frequently reported with use of the murine monoclonal antibody OKT3 [120-123]. In lung, heart, and renal transplant recipients, in both pediatric and adult patients, numerous trials have been performed without reported incidence of cytokine release syndrome with use of daclizumab or basiliximab [25, 122, 124, 125]. Serum sickness is an immune complexmediated disease that results from circulating antibodies against foreign animal epitopes present in the antithymocyte globulin preparations. Patients present with fever, arthritis, rash, and lymphadenopathy. Renal failure may also occur when immune complexes are deposited in the kidneys resulting in nephritis [126]. Serum sickness has been reported following treatment with the polyclonal antibodies antithymocyte globulins ; in solid organ transplant recipients [126, 127]. The incidence following treatment with polyclonal antibodies ranges from 7% to 27%. Prin Mathieu et al [126] reported an incidence of serum sickness of 18% in 89 renal transplant recipients who underwent induction therapy with horse or rabbit antilymphocyte globulins. Although the disease is generally self-limited, its resolution might be augmented by use of steroid therapy; plasma exchange has been successfully used in severe cases [127]. That's why i think, if there is an anaerobic infection, and clindamycin isn't working out, flagyl is the best bet and clobetasol. Therapy directed primarily at S. aureus and streptococci: amoxicillin clavulanate cefazolin, cefuroxim, clindamycin ; Limb-threatening diabetic foot ulcer; Immunosuppression: + P. aeruginosa, Enterobacteriaceae: piperacillin tazobactam imipenem cilastatin, meropenem ; Exposure to fresh water: + Aeromonas spp.: amoxicillin clavulanate + ciprofloxacin Exposure to salt water: + Vibrio vulnificus: amoxicillin clavulanate + doxycycline switch to p.o. when pts. afebrile and skin findings begin to resolve after 3-5 d. Total duration of Th.: 7-14 days. Just because i have provided this resource for you does not mean i condone these drugs and clotrimazole, for example, clindamycin dosage. Skin reaction to clindamycinPrescription DrugsImportant. In addition to human resources, a technical institutional base like TFNC has proven very useful. It has the legal and executive function with regard to food and nutrition, promoting coordination and integration with other nutritional problems. The TFNC provides a national coordinating mechanism for several different nutritional problems, and also serves as a base for negotiating support for both the government and donors. In this program it was also found that the first target for advocacy should be the medical profession because if not convinced, it can delay implementation of programs. Several practical points emerged from the development of these programs. One is that programs must be developed in an orderly way rather than prematurely. It requires some time to build up confidence in a national perspective and ownership of programs. Dr. Kavishe noted that there is always a trade-off between wanting to be completely prepared and getting things done. His conclusion was that program should be technically sound, and that its start may have a very large advocacy effect. Regarding targeting, he noted that it may be more cost effective, but perhaps at the price of community acceptance. Monitoring should be included from the beginning of the program, and the chosen indicators identified. Finally, in the communications efforts, it is essential to identify the target group. It is all too common to concentrate advocacy efforts on those already convinced. Tanzania has the goal of eliminating IDD by the year 2000. With iodized oil capsules, it expects to virtually eliminate severe IDD by 1993. The iodized oil program can be slowly phased out as iodized salt takes over, and the target date for that is 1995. However, it is recognized that the successful implementation of iodized salt may take somewhat longer, and monitoring will be essential to determine when iodized oil is no longer necessary. In summarizing, the success so far of the Tanzania program is attributed in large part to the following factors: conceptionalization of the problem in which the micronutrient deficiencies are seen as outcomes of processes in society with immediate underlying and basic causes; the emphasis on program development, in which assessment analysis and action were carried out at both national and community levels; the presence of technically competent and interested nationals; the presence of a technical and managerial institutional base, the TFNC, which made multisectoral coordination possible; the emphasis on communication to achieve widespread public understanding of the problems; frequent internal and external process evaluations; establishment of national and international contacts and linkages with individuals and organizations with technical managerial and mobilizational expertise; and a favorable political commitment strongly advocating social action. IDD control program in Ecuador was described by Dr. Mauro Rivadeneira, ICCIDD Board Member and Director of the Ecuadorean Belgian Cooperative Program Against IDD. Although a 1968 law made the use of iodized salt compulsory, there was little progress in its implementation. A survey in the 1980's showed that half of the total population, about 5 million people living in the highlands, was at risk for iodine deficiency. The bilateral agreement between the government of Belgium and the Ecuador Ministry of Public Health began an aggressive program in the mid-1980's. It developed a quick and efficient operational methodology with the objectives of guaranteeing that salt for human consumption has an adequate concentration of iodine and increasing its use among the rural population, the group at highest risk. Many medical conditions can be treated more effectively with dietary changes and nutritional supplementation than they can by other means and cyproheptadine. Pharyngitis cont'd ; Gonococcal Neisseria gonorrhoeae * Cefixime or Ciprofloxacin Alternative Ceftriaxone + * Azithromycin or Doxycycline Penicillin + Metronidazole IV POC -lactam allergy Clindamycni IV POC Surgical drainage as appropriate + Penicillin + C Metronidazole IV PO -lactam allergy C Cindamycin IV PO Surgical drainage + Penicillin + Metronidazole IV POC -lactam allergy Clindamycij * IV POC 400mg PO 500mg PO 125mg IM 1g PO 100mg PO bid 4MU IV q4h 500mg IV PO q12h 600mg IV q8h or 300mg PO qid 3-4MU IV q4h 500mg IV PO q12h 600mg IV q8h or 300mg PO qid 3-4MU IV q4h 500mg IV PO q12h single dose single dose single dose single dose 7 days 10 days 10 days - May occur as a rare complication of AOM children ; , tonsillitis younger adults ; , or dental infections older adults ; . * Notify lab if clinically suspected. Submit specimen in charcoal transport medium. * All regimens should be followed by empiric treatment for chlamydial infection. Colleagues and staff at the Department of Psychiatry at St. Grans Hospital, especially associated Professor Bengt Kjellman for his enthusiasm, support and encouragement, Anita Frlin for her kindness and appreciated secretarial assistance, Birgitta Norberg for her help and assistance with patient recruitment and sample collection when needed and Lars Bejhed for computer assistance and for our amusing chats about sports particularly football ; . My former teachers and school staff throughout the years, especially Agneta holm, Kurt Rnnbeck, Karin Jords and Maurice Georgi Krsbyskolan ; , Anita Kretz and Lillemor Bylund Botvidsgymnasiet ; , Uno Svensson Uppsala Universitetet ; and Gunnel Lrka-Rafner Hlsohgskolan, Stockholm ; . All my friends, particularly Shukri, Can, George, Augin, Matias, Lennart, Patrik and fellow-football players in Arameiska Syrianska KIF. I would also like to thank my colleagues at the Pharmacy Grisslan in Skrholmen, especially Lisbeth, Sohrab, Sylvia, Ingrid and Dimitra. Thank you all for valued friendship! My grandmother Ema, the most tender and kind-hearted person on earth, my uncles Dr. Elias, Jacoub, Dr. Marwan, Jean and aunt Farida with families, for love and support. My dear parents Fr. Chabo and Naward, my brothers Jean and Tony with families and my sister Rania with family for sincere love, understanding and support through all these years. Thank you all for making life great! My most beloved and faithful wife Maria, who provided me with invaluable and endless love, care and understanding. Thank you for all patience with me during these years. Without your inestimable support, this thesis would not have been possible! My daughters and sweet princesses Edessa and Simona, for providing invaluable happiness and delight in my life. Financial support was provided by grants from the Swedish Medical Council, Pharmacia & Upjohn and Karolinska Institutet in Stockholm, Sweden and diamicron. Tration. J Mich Dent Assoc 2005; 87: 4449. Sitters MA, Caldwell CS. Bisphosphonates, dental care and osteonecrosis of the jaws. Tex Dent J 2005; 122: 968972. Ficarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005; 32: 1123 Pastor-Zuazaga D, Garatea-Crelgo J, Martino-Gorbea R, Etayo-Prez A, Sebastin-Lpez C. Osteonecrosis of the jaws and bisphosphonates: report of three cases. Med Oral Patol Oral Cir Bucal 2006; 11: 7679. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653661. Jones JR, Lehtinen T, Riphagen FE, von Roemeling R. Adverse event AE ; reporting of oral clodronate with emphasis on osteonecrosis of the jaws. J Clin Oncol 2005; 23 16S ; : 799. 85. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18: 7585. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates [letter]. N Engl J Med 2005; 353: 99102, for example, generic clindamycin. On the leg, which was treated with topical care and cephalexin. A culture grew MRSA resistant to tetracycline and clindamycin. Therapy was changed to trimethoprim-sulfamethoxazole and cleaning with topical chlorhexidine was added. Meanwhile, the mother sought care for a skin papule, was diagnosed with an insect bite and cellulitis, and was given azithromycin. She returned for care after the infection worsened; by that time she knew her child had MRSA, and she was given empiric trimethoprim sulfamethoxazole. The next day, the father was cultured for a new lesion that grew MRSA sensitive to tetracycline, and was treated with clindamycin. A 5-year-old son was not affected. The entire family used topical chlorhexidine on the skin and mupirocin in the nares for 3 days. On follow up 2 months later, they had all healed with no recurrences, but subsequently recurrences in the father and child were reported and diclofenac. Drug Name & Dosage CLEMASTINE 0.67MG 5ML SYRUP AMINOPHYLLINE 105MG 5ML LIQ ACETASOL 2% EAR SOLUTION ACETASOL HC EAR DROPS TRI-VIT FLUOR .25MG DROPS TRI-VIT FLUOR .5MG DROPS DEXAMETHASONE 0.5MG 5ML ELX DEXAMETHASONE 0.5MG 5ML ELX CLINDAMYCIN PH 1% SOLUTION POTASSIUM CHLORIDE 10% LIQ POTASSIUM CHLORIDE 10% LIQ PHENOBARBITAL 20MG 5ML ELIX PHENOBARBITAL 20MG 5ML ELIX PHENOBARBITAL 20MG 5ML ELIX SULFATRIM SUSPENSION METAPROTERENOL 0.4% SOLN METAPROTERENOL 0.6% SOLN BETAMETHASONE DP 0.05% LOT ACETAMINOPHEN COD ELIXIR ACETAMINOPHEN COD ELIXIR ACETAMINOPHEN COD ELIXIR THEOPHYLLINE 80MG 15ML ELIX PROMETHAZINE 6.25MG 5ML SYR MICONAZOLE 3 200MG VAG SUPP FLUOCINONIDE 0.05% CREAM FLUOCINONIDE 0.05% CREAM FLUOCINONIDE 0.05% CREAM NYSTATIN 100000U GM OINT NYSTATIN 100000U GM OINT BETAMETHASONE VA 0.1% LOT BETAMETHASONE DP 0.05% LOT MICONAZOLE 3 200MG VAG SUPP VALPROIC ACID 250MG 5ML SYR MORPHINE SULF 20MG ML SOLN MORPHINE SULF 10MG 5ML SOLN TETRACYCLINE 500MG CAPSULE TETRACYCLINE 500MG CAPSULE TETRACYCLINE 250MG CAPSULE DIPHENHYDRAMINE 50MG CAPS DIPHENHYDRAMINE 50MG CAPS ISONIAZID 100MG TABLET ISONIAZID 100MG TABLET ISONIAZID 300MG TABLET ISONIAZID 300MG TABLET ISONIAZID 300MG TABLET DIAZEPAM 2MG TABLET DIAZEPAM 2MG TABLET ERYTHROMYCIN 200MG 5ML GRAN ERYTHROMYCIN 200MG 5ML GRAN DIPYRIDAMOLE 25MG TABLET DIPYRIDAMOLE 25MG TABLET DIPYRIDAMOLE 25MG TABLET SULFINPYRAZONE 100MG TABLET SULFINPYRAZONE 200MG CAP OXYCODONE W APAP 5 325 TAB DIPYRIDAMOLE 50MG TABLET DIPYRIDAMOLE 50MG TABLET DIPYRIDAMOLE 75MG TABLET DIPYRIDAMOLE 75MG TABLET HYDROXYZINE PAM 50MG CAP HYDROXYZINE PAM 50MG CAP HYDROXYZINE PAM 25MG CAP HYDROXYZINE PAM 25MG CAP HYDROXYZINE PAM 100MG CAP MEPERIDINE 50MG TABLET PROPRANOLOL HCTZ 80 25 TAB ACETOHEXAMIDE 250MG TABLET. Upon receipt of a new prescription or a new prescription drug order, following a review of the patient's record, and upon acceptance of an offer to consult, a pharmacist shall personally initiate discussion of matters, which, in the professional judgment of the pharmacist, will enhance or optimize drug therapy with each patient or the agent or caregiver of the patient. The discussion shall be in person, whenever practicable, may be supplemented with written material, and shall include appropriate elements of patient counseling. These elements include the following: A. the name and description of the drug; B. the dosage form, dose, route of administration, and duration of drug therapy; C. intended use of the drug and expected action; D. special directions and precautions for preparation, administration and use by the person; E. common severe side affects, adverse affects, or interactions and therapeutic contraindications that may be encountered including their avoidance and the action required if they occur; F. techniques for self-monitoring of drug therapy; G. proper storage; H. prescription leaflet information; I. action to be taken in the event of a misdose; J. pharmacist comments relevant to the patient's drug therapy including any other information peculiar to the specific patient or drug. If a prescription drug has been previously dispensed to a patient, the pharmacist or the pharmacist designee shall attempt to determine if the patient has experienced any unexpected or unusual reactions or changes in health, whether the patient has experienced the expected outcome, whether the patient is using the medication as prescribed, and whether the patient has been using any over-the-counter or prescription drugs not in the patient's record since the last visit to the pharmacy. If the pharmacist's review of the patient's record or discussions with the patient reveal any of the conditions listed in part 6800.3110, subp. 4, the pharmacist or the pharmacist's designee must offer counseling by the pharmacist to the patient or the patient's agent or caregiver and dimenhydrinate. Clindamycin capsule identificationA new neurological symptom that persists for than 24 hrs. No better explanation, i.e. fever. Worsening of a neurological symptom that had been stable for at least 30 days. Persists for than 24 hours. No better explanation and dramamine and clindamycin, for example, metronidazole vs clindamycin. Resistance to clindamycin
|